← Leaderboards
Ulrich Specks
Mayo Clinic Coll Of Medicine, Rochester
$1,219,165
Attributed
$1,219,165
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,219,165 · 3
By mechanism
R01$1,000,532 · 1
R21$203,430 · 1
M01$15,203 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Steven A Vernino$5,812,716
- Moses Rodriguez$7,609,151
- Chella S David$12,457,836
- Phillip A Low$10,116,600
- Rebecca S Bahn$5,415,200
Others in their field
Top investigators on “Autoantibody”
- Jeffrey P Krischer · University Of South Florida$214,327,112
- Dorothy J Becker · Children'S Hosp Pittsburgh/Upmc Hlth Sys$36,769,044
- Marian J. Rewers · University Of Colorado Denver$35,235,150
- Russell E Ware · Duke University$33,922,841
- Betty Diamond · Feinstein Institute For Medical Research$31,327,232
- V Michael Holers · University Of Colorado Denver$25,425,841
Research focus
AutoantibodyWegener'S GranulomatosisSerine ProteinasesHuman TissueClinical ResearchDisease /Disorder ClassificationNeutrophilPatient Oriented ResearchProtein IsoformsBiomarkerEndopeptidasesImmunopathologyMolecular PathologyAutoantigensMyeloperoxidaseGene ExpressionGenetically Modified AnimalsPolymerase Chain ReactionCell TransplantationPhenotypeHybrid AntibodyImmunofluorescence TechniqueAntigen Antibody ReactionModel Design /Development
Grant awards (8)
PR3-ANCA Subsets and Disease Phenotype$222,684
R01 · FY2005 · AR
PILOT TRIAL OF RITUXIMAB (RITUXAN) IN ANCA-ASSOCIATED VASCULITIS$6,397
M01 · FY2005 · RR
PR3-ANCA Subsets and Disease Phenotype$255,793
R01 · FY2004 · AR
Trial of Rituximab in ANCA-Associated Vasculitis$8,806
M01 · FY2004 · RR
PR3-ANCA Subsets and Disease Phenotype$256,295
R01 · FY2003 · AR
PR3-ANCA Subsets and Disease Phenotype$265,760
R01 · FY2002 · AR
EFFECTS OF PR3-ANCA ON DISEASE PHENOTYPE$99,660
R21 · FY2001 · AI
EFFECTS OF PR3-ANCA ON DISEASE PHENOTYPE$103,770
R21 · FY2000 · AI